What is Ceribell?
Founded in 2014 by Stanford University faculty, Ceribell is a venture-backed medical device company that has developed an FDA-cleared, point-of-care EEG system. This innovative technology aims to make the diagnosis of neurological conditions, particularly seizures, significantly more efficient and accessible. Ceribell's mission is to democratize EEG accessibility, reduce diagnostic wait times, and lower costs for healthcare providers, thereby improving patient outcomes. The company's development of a user-friendly EEG system that does not require specialized technicians for setup or immediate interpretation addresses critical unmet needs in clinical settings.
How much funding has Ceribell raised?
Ceribell has raised a total of $171M across 4 funding rounds:
Series A
$13M
Series B
$35M
Debt
$20M
Series C
$103M
Series A (2017): $13M with participation from DHVC and Shangbay Capital
Series B (2018): $35M led by Optimas Capital Partners Fund, UCB, LivaNova, and The Rise Fund
Debt (2020): $20M supported by Horizon Technology Finance Corporation
Series C (2021): $103M featuring Redmile Group, RA Capital Management, Red Tree Venture Capital, Ally Bridge Group, Longitude Capital, and The Rise Fund
Key Investors in Ceribell
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools. RA Capital aims to partner with innovators to bring ideas from the lab to the clinic, ultimately improving patient lives.
The Rise Fund
The Rise Fund is an impact investing platform that focuses on investing in growth-stage, mission-driven companies aligned with the United Nations' Sustainable Development Goals. The fund specializes in multiple sectors including climate and conservation, education, food and agriculture, financial inclusion, healthcare, and impact services.
UCB
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology. Founded in 1928, UCB is headquartered in Brussels, Belgium.
What's next for Ceribell?
With substantial enterprise-level backing and a recent strategic investment, Ceribell is poised for accelerated growth and market expansion. The company's focus on enhancing the efficiency and accessibility of EEG diagnostics positions it to capture a significant share of the neurological monitoring market. Future strategic initiatives are likely to involve further product development, scaling manufacturing capabilities, and expanding its commercial reach into new healthcare systems and international markets. The sustained investor confidence, evidenced by the significant capital raised, suggests a strong belief in Ceribell's technology and its potential to transform patient care in neurology.
See full Ceribell company page
